Brief: Clarity Pharmaceuticals Says It Got IND Approval By US FDA For Theranostic Sar-Bombesin Trial
20/11/2022 23:02
Nov 21 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* IND APPROVAL FROM US FDA FOR THERANOSTIC SAR- BOMBESIN
TRIAL IN
PROSTATE CANCER
Source text for Eikon: ID:nASXv1GPp
Further company coverage: CU6.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial